Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Image

[Articles] First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial

Journal content Created on 26 Oct 2026 The Lancet

Published in

The Lancet, The Lancet (Reed Elsevier)

Content

There is no additional content. Please click on the source link to view more information.

Advertisement

Stats

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 42
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement